Chris is a Venture Partner at Apollo and leads severalportfolio companies after incubation
Chris co-founded Avogadro Development Corp and Structured BioEquity. He was also the CEO of SmartZyme Biopharma, an OrbiMed portfolio company, where he was in charge of the company’s R&D efforts and an global investor base.
In the previous years he supported over $1.5bn in investments and transactions in biotechnology/pharma spanning research, drug program development, combination product development, clinical trial design, and personalized medicine and biomarkers.
Chris started his career at Genentech where he worked on the development of several medicines and a number of pipeline assets. He earned his PhD in Molecular and Cellular Pathology at the University of Pittsburgh Medical School of Medicine
Chris is a Venture Partner at Apollo and leads severalportfolio companies after incubation
Chris co-founded Avogadro Development Corp and Structured BioEquity. He was also the CEO of SmartZyme Biopharma, an OrbiMed portfolio company, where he was in charge of the company’s R&D efforts and an global investor base.
In the previous years he supported over $1.5bn in investments and transactions in biotechnology/pharma spanning research, drug program development, combination product development, clinical trial design, and personalized medicine and biomarkers.
Chris started his career at Genentech where he worked on the development of several medicines and a number of pipeline assets. He earned his PhD in Molecular and Cellular Pathology at the University of Pittsburgh Medical School of Medicine
